Program
LY3884961
A development code.
In Eli Lilly's pipeline, GBA1 gene therapy
. Its studies are mostly in Parkinson Disease, led by Eli Lilly.
Furthest: phase 2, since Oct 14, 20191 company-led study, 1 open or runningNext primary completion: Aug 31, 2031 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 11 open or running | phase 2since Oct 14, 2019 | Oct 14, 2019 | Aug 31, 2031phase 2 · NCT04127578 |
- Named in Eli Lilly’s own pipeline as
GBA1 Gene Therapy
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 14, 2019First study: phase 2 study in Parkinson DiseaseFirst studyNCT04127578 · 32 enrolled · United States, Israel
Ahead
- Aug 31, 2031Primary completion: phase 2 study in Parkinson DiseaseNCT04127578
TargetBeta
“GBA1 gene therapy”the company's pipeline, read by Claude · source
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04127578Parkinson Disease · United States, Israel | 2 | Active, not recruiting | Aug 31, 2031 | 32 |
How it is read
Names in the registry
- “LY3884961”, 1 entry
Codes read as this program: LY3884961.
Conditions, from the studies’ own filings
- Parkinson Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.